• Center on Health Equity and Access
  • Clinical
  • Health Care Cost
  • Health Care Delivery
  • Insurance
  • Policy
  • Technology
  • Value-Based Care

Dr Marie D'hooghe Discusses How Pregnancy Affects Disease Course in Patients With MS

Video

Some data suggest that pregnancy may be beneficial in the long-term for patients with multiple sclerosis (MS), but there exist periods that may carry an extra risk of relapse, such as before conception and in the postpartum period, according to Marie D’hooghe, MD, PhD, neurologist at the National MS Center, Melsbroek, in Brussels, Belgium, and consultant neurologist at the University Hospital in Brussels, Belgium.

Some data suggest that pregnancy may be beneficial in the long-term for patients with multiple sclerosis (MS), but there exist periods that may carry an extra risk of relapse, such as before conception and in the postpartum period, according to Marie D’hooghe, MD, PhD, neurologist at the National MS Center, Melsbroek, in Brussels, Belgium, and consultant neurologist at the University Hospital in Brussels, Belgium.

Transcript

What is the current state of knowledge on how pregnancy affects disease course in MS?

There have been some observational studies that have indicated that pregnancy might have maybe a beneficial effect in the long term. But we have to be so careful, because maybe only—and probably only—these patients who have a mild disease course get pregnant, and those patients that have a more severe disease course, they don’t get pregnant. So, the observations might be distorted by the fact that more mild MS patients are choosing pregnancy.

So, that’s a difficult one. In the short term, we know that pregnancy is actually quite well tolerated. Especially in the second and the third trimester; there is even a reduction of relapses. But in the postpartum period, just after giving birth, there is an increased risk of relapses, which is not the case in all patients, but there is some increased relapse risk after giving birth. So, it’s important to support this period and to keep in mind that this might happen—to tell the patient that, in the short term, this is a kind of a risky period.

What is also a risky period is when patients start on a treatment, when they’re getting diagnosed, they start on a treatment, and then they want to get pregnant. So then the question is, do you start treatment that can be continued until conception, or do you start treatment that has to be stopped before conception? Of course, we do not know when the patient will conceive, because the period might change from 6 months to 24 months. So in this period, the patients might have relapses, and might have disease activity.

On the other hand, if we have very active treatments that have to be stopped before pregnancy, we risk some kind of rebound activity, and if this occurs during pregnancy, pregnancy will not protect against this rebound activity, and actually, the patient may do worse.

Related Videos
Screenshot of Stephen Freedland, MD, during a video interview
Phaedra Corso, PhD, associate vice president for research at Indiana University
William Padula, PhD, MSc, MS, assistant professor of pharmaceutical and health economics, University of California Alfred E. Mann School of Pharmacy and Pharmaceutical Sciences
Screenshot of Angela Jia, MD, PhD, during a video interview
Nancy Dreyer, MPH, PhD, FISE, chief scientific advisor to Picnic Health
Screenshot of Alexander Kutikov, MD, during a video interview
Neil Goldfarb, CEO, Greater Philadelphia Business Coalition on Health
Screenshot of Mary Dunn, MSN, NP-C, OCN, RN, during a video interview
Seth Berkowitz, MD, MPH, associate professor of medicine, University of North Carolina at Chapel Hill
Inma Hernandez, PharmD, PhD, professor at the University of California, San Diego Skaggs School of Pharmacy and Pharmaceutical Sciences
Related Content
© 2024 MJH Life Sciences
AJMC®
All rights reserved.